Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant

Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32

DIETARY_SUPPLEMENT

conjugated linoleic acid (CLA)

3.2 g/day, capsule, week 0 to week 32

DIETARY_SUPPLEMENT

conjugated linoleic acid (CLA)

6.4 g/day, capsule, week 0 to week 32

Trial Locations (1)

43210

The Ohio State University Clinical Research Center (Davis Medical Research Center), Columbus

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Bunge Loders Croklaan

INDUSTRY

collaborator

LifeScan

INDUSTRY

lead

Ohio State University

OTHER